Brain metastases requiring steroids
Has clinically active brain metastases, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with steroids may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 4 weeks must have elapsed between the end of whole brain radiotherapy and study enrollment (2 weeks for stereotactic radiotherapy).
Patients with known symptomatic brain metastases requiring steroids in part 1 or 2
Patients with untreated symptomatic brain metastases may be eligible if symptoms do not require urgent surgery or radiation, and no steroids are necessary
Has clinically active brain metastases, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms (participants with treated brain metastases that are no longer symptomatic and who require no treatment with steroids may be included in the study if they have recovered from the acute toxic effect of radiotherapy)
Patients with known symptomatic brain metastases requiring steroids
Brain metastases unless asymptomatic, stable and not requiring steroids for at least 2 weeks
Symptomatic brain metastases or brain metastases requiring chronic steroids to control symptoms.
Known symptomatic brain metastases requiring steroids.
Patients with known symptomatic brain metastases requiring steroids.
Presence of symptomatic brain metastases requiring immediate treatment with radiation therapy or steroids.
Presence of symptomatic brain metastases requiring immediate treatment with radiation therapy or steroids.
Presence of symptomatic brain metastases requiring immediate treatment with radiation therapy or steroids.
Participants with symptomatic brain metastases that require chronic steroids are excluded; patients with a history of brain metastases are permitted to enroll as long as they have been treated, off of steroids and have been stable for one month on imaging
Symptomatic brain metastases or brain metastases requiring chronic steroids to control symptoms.
Brain metastases requiring steroids
Patients with known brain metastases requiring steroids.
Participants with symptomatic or progressive brain metastases, or requiring steroids to control symptoms of brain metastases
Known untreated, symptomatic, or progressive brain metastases; presence of carcinomatous meningitis; history of intracranial hemorrhage; or brain metastases requiring chronic steroids
Any known symptomatic brain metastases requiring steroids. Patients with treated brain metastases must be stable for 4 weeks after completion of that treatment, with image documentation required. Patients must have no clinical symptoms from brain metastases and must be either off steroids or on a stable dose of steroids for at least 2 weeks prior to protocol enrollment. Patients with known leptomeningeal metastases are excluded, even if treated.
Unstable or symptomatic brain metastases (however, patients with stable or treated brain metastases who do not require steroids at doses above those permitted for control of symptoms may be enrolled)
Patients with known symptomatic brain metastases requiring steroids.
Brain metastases requiring steroids
Brain metastases requiring steroids.
Any known symptomatic brain metastases requiring steroids.
Patients with known symptomatic brain metastases requiring steroids
Brain metastases requiring steroids
Has clinically active brain metastases, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with steroids may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 4 weeks must have elapsed between the end of whole brain radiotherapy and study enrollment (2 weeks for stereotactic radiotherapy).
Brain metastases that are:\r\n* Progressive or\r\n* Have required any type of therapy (including radiation, surgery or steroids) to control symptoms from brain metastases within 60 days prior to the first study treatment
Brain metastases with symptoms or requiring treatment
Any known symptomatic brain metastases requiring steroids. Patients with treated brain metastases must be stable for 4 weeks after completion of that treatment, with image documentation required. Patients must have no clinical symptoms from brain metastases and must be either off steroids or on a stable dose of steroids for at least 2 weeks prior to protocol enrollment. Patients with known leptomeningeal metastases are excluded, even if treated
Clinically active brain metastases, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with steroids may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 4 weeks must have elapsed between the end of whole brain radiotherapy and study enrollment (2 weeks for stereotactic radiotherapy).
Participants must not have symptomatic brain metastases or brain metastases requiring steroids; asymptomatic brain metastases not requiring steroids are acceptable
Brain metastases that are untreated, symptomatic, or require therapy to control symptoms, as well as any history of radiation, surgery, or other therapy, including steroids, to control symptoms from brain metastases within 1 month (30 days) of enrollment.
No symptomatic brain metastasis; (note: patients with treated brain metastasis must be off steroids or on tapering or stable doses of steroids and have completed radiation at least 14 days prior to registration for protocol therapy)
Symptomatic brain metastasis requiring corticosteroids
Subjects with symptomatic brain metastases will be excluded from trial secondary to poor prognosis; however, subjects who have had treatment for their brain metastasis and whose brain disease is stable without steroid therapy for 1 week or on physiologic doses of steroids may be enrolled
Symptomatic brain metastasis
Patients with symptomatic brain involvement
Melanoma patients with large or symptomatic brain metastasis, and in whom neurosurgical removal is indicated will not be eligible for this trial
Symptomatic or untreated brain metastasis
Subjects with symptomatic brain metastases will be excluded from trial secondary to poor prognosis; however, subjects who have had treatment for their brain metastasis and whose brain disease is stable without steroid therapy for at least 3 months may be enrolled
Symptomatic brain metastasis
The subject has untreated, symptomatic or uncontrolled brain metastasis requiring current treatment including steroids and anti-convulsants; neurosurgical resection of brain metastasis or brain biopsy is permitted if completed at least 3 months before the first dose of study treatment
Uncontrolled or symptomatic brain metastasis
Patients with any metastasis in the brain or meninx that is symptomatic or requires treatment
Patients with uncontrolled symptomatic brain metastases; a scan to confirm absence of brain metastasis is not required
Subject has a history of, or current symptomatic brain metastasis.
The patient has a primary brain tumor(s) or brain metastasis (unless metastasis is treated and stable for > 28 days). In patients who are symptomatic, a brain scan is required to exclude metastasis.
Symptomatic brain metastasis
Symptomatic or uncontrolled brain metastasis or epidural disease requiring current treatment including steroids and anti-convulsant
Symptomatic brain metastasis
Patients with symptomatic brain metastasis requiring escalating doses of steroids
Symptomatic uncontrolled brain metastasis
Patients who are symptomatic from brain metastasis
Symptomatic brain metastasis. Participants with brain metastases:
Patients with symptomatic brain metastasis requiring escalating doses of steroids
Known active, or symptomatic, brain metastasis
Symptomatic brain metastasis; patients with treated brain metastasis must be completely weaned off of steroid therapy for at least 14 days prior to starting protocol therapy
No clinical neurologic signs or symptoms of brain metastasis (brain imaging only required for symptomatic individuals per 2014 National Comprehensive Cancer Network [NCCN] Guidelines)
Patients with any known brain or leptomeningeal metastases are excluded, even if treated.
Untreated or symptomatic brain metastases and leptomeningeal disease
Patients with brain metastases (treated or untreated) leptomeningeal disease, uncontrolled seizure disorder, or active neurologic disease
Patients with evidence of active brain metastases, or active leptomeningeal disease are ineligible; patients with a history of brain metastases must have completed treatment (i.e. surgery or radiation) prior to enrollment
Patients with uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
No history or evidence by CT scan or MRI, of brain metastases or leptomeningeal disease.
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases; asymptomatic or treated brain metastases are acceptable
Uncontrolled brain or leptomeningeal metastases from plexiform neurofibromas, malignant peripheral nerve sheath tumors, or other cancers (other than proven or probable low grade astrocytomas), including patients who continue to require glucocorticoids for control of symptoms related to brain or leptomeningeal metastases
Subjects with known symptomatic brain metastases or leptomeningeal metastases
Any known brain or leptomeningeal metastases are excluded, even if treated.
Have symptomatic brain metastases or leptomeningeal disease
Known brain metastases or leptomeningeal disease involvement. Glioblastoma lesions (primary or locally advanced) are eligible.
Known brain or leptomeningeal metastases
Subject has known symptomatic brain metastases or leptomeningeal involvement as assessed by CT scan or MRI. Subjects with stable asymptomatic brain metastases or leptomeningeal disease are eligible provided that they have not required new treatments for this disease in a 28 day period before the first dose of study drug, and anticonvulsants and steroids have not been administered for a period of 2 weeks prior to the first dose of study drug.
Known symptomatic uncontrolled brain or leptomeningeal metastases (Day 1)
Patients who have known leptomeningeal metastases or untreated or symptomatic brain metastases; treated, asymptomatic brain metastasis can be included
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases.
Patients who have a primary brain tumor (excluding meningiomas and other benign lesions), any brain metastases, leptomeningeal disease, seizure disorders not controlled with standard medical therapy, or history of stroke within the past year
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Current or previously treated brain or leptomeningeal metastases
Current or previously treated brain or leptomeningeal metastases
Clinical evidence of symptomatic progressive brain or leptomeningeal disease during the past 6 months
Known active brain or leptomeningeal metastases (defined as symptomatic metastases) or continued requirement for glucocorticoids for brain or leptomeningeal metastases; treated, asymptomatic metastases are permitted provided the patient has been off steroids for at least 4 weeks prior to day 1 of study drug
Known or suspected leptomeningeal disease; patients with metastases to the brain stem, midbrain, pons or medulla
Untreated brain metastases, treated brain metastases that are not stable, leptomeningeal disease, or seizures uncontrolled with standard medical therapy
Patients who have a primary brain tumor (excluding meningiomas and other benign lesions), any brain metastases, leptomeningeal disease, seizure disorders not controlled with standard medical therapy, history of stroke within the past year
Documented and/or symptomatic or known brain or leptomeningeal metastases
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Uncontrolled brain or leptomeningeal metastases, including those who continue to require glucocorticoids for brain or leptomeningeal metastases
Clinical signs of brain involvement or leptomeningeal disease
Untreated brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Untreated brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Extensive active brain disease including symptomatic brain metastases or presence of leptomeningeal disease
Patients with symptomatic brain metastases who have not completed radiation therapy and/or are receiving systemic steroid therapy; patients with leptomeningeal disease will be excluded
Brain metastases or active leptomeningeal disease (with the exception of participants with treated epidural disease and no other epidural progression)
The participant has documented brain metastases or leptomeningeal disease.
Confirmed brain and/or leptomeningeal metastases
Patients with known active brain or central nervous system metastases, including leptomeningeal disease; patients with treated and asymptomatic brain metastases may be eligible after discussion with PI
Patients must not have symptomatic uncontrolled brain or leptomeningeal metastases.
Any brain metastases including leptomeningeal metastases, are excluded, even if treated and stable.
Documented or symptomatic brain metastases and/or central nervous system metastases or leptomeningeal disease
Active brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases; treated, asymptomatic metastases are permitted provided the patient has been off steroids for at least 1 month prior to day 1 of study drug
Prior brain or leptomeningeal metastases allowed if asymptomatic (e.g., diagnosed incidentally at study baseline)
Subject has known or suspected primary brain or leptomeningeal metastases
Subject has known symptomatic brain metastases or leptomeningeal involvement as assessed by CT scan or MRI. Subjects with stable asymptomatic brain metastases or leptomeningeal disease are eligible if they have not required new treatments for this disease in a 28 day period before the first dose of study drug, and anticonvulsants and steroids have not been administered for a period of 2 weeks prior to the first dose of study drug.
Brain metastases or leptomeningeal disease
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Expansion A:\r\n* Brain metastases or leptomeningeal not previously treated with radiation or surgery
Metastatic brain or leptomeningeal tumors (treated metastatic brain or leptomeningeal tumors are allowed)
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
A history of or evidence of brain metastases or leptomeningeal disease.
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Patients with brain or central nervous system metastases, including leptomeningeal disease
Leptomeningeal disease or any untreated or symptomatic brain metastases, unless the following criteria are met:
Known symptomatic brain mets or leptomeningeal involvement
Known brain, leptomeningeal or epidural metastases (unless treated and well controlled for at least 3 months)
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Brain metastases, leptomeningeal disease, uncontrolled seizure disorder, or active neurologic disease
Brain or leptomeningeal metastases that are symptomatic and/or requiring treatment
No known or suspected (associated neurological signs and symptoms) brain metastases (including leptomeningeal involvement)
Patients with brain metastases (treated or untreated) leptomeningeal disease, uncontrolled seizure disorder, or active neurologic disease
Uncontrolled brain metastases or leptomeningeal involvement; patients with brain metastases are permitted if they have received appropriate therapy and demonstrated control of the brain metastases or leptomeningeal disease following therapy; patients with known brain metastases will require magnetic resonance imaging (MRI) brain to demonstrate disease control prior to enrollment (lack of symptom progression for two weeks off therapeutic doses of steroids, excluding chronic steroids used for control of chronic obstructive pulmonary disease [COPD])
Subjects with brain metastases, leptomeningeal disease, uncontrolled seizure disorder, or active neurologic disease
Patients with untreated or uncontrolled brain metastases or leptomeningeal disease
Current or a prior history of brain metastases or leptomeningeal disease. Must not have rapidly progressive, life-threatening metastases.
Symptomatic uncontrolled brain or leptomeningeal metastases
Symptomatic uncontrolled brain or leptomeningeal metastases.
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
Known brain metastases not radiographically stable for ?3 months or leptomeningeal disease
Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases; treated brain metastases must have been stable for at least 2 months
Uncontrolled brain or all leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
The participant has uncontrolled brain or leptomeningeal metastases
Untreated or symptomatic brain metastases or leptomeningeal disease
Symptomatic, progressive or corticosteroids-requiring documented brain metastases or leptomeningeal disease involvement.
No current symptomatic, untreated, or uncontrolled brain metastases present
Clinical or radiologic evidence of new, untreated, and/or progressive brain metastases prior to registration after induction systemic therapy.
COHORT A: Previously untreated asymptomatic brain metastases
Untreated or clinically active melanoma brain metastases.
Participant has untreated brain or meningeal metastases.
Active or untreated brain metastases
Patients with untreated known brain metastases, or treated brain metastases that are clinically unstable
History of brain metastases or who currently have treated or untreated brain metastases
Untreated brain metastases
Untreated brain metastases, if not planned to be treated in this course of radiation therapy
Untreated brain metastases
Known untreated or symptomatic brain metastases
Untreated, progressing, or symptomatic brain metastases
Known active and/or untreated brain metastases
Symptomatic or untreated brain metastases
One to 4 untreated metastatic brain lesions
Metastatic melanoma or non-squamous NSCLC with untreated brain metastases
Progressive, symptomatic untreated brain metastases
Must not have untreated brain metastases
Symptomatic and/or untreated Brain Metastases
Untreated brain metastases
Patients with untreated brain or meningeal metastases
Untreated, progressing, or symptomatic brain metastases
Untreated brain metastases (or local treatment of brain metastases within the last 6 months)
Patients with brain metastases that are untreated, symptomatic, or require therapy to control symptoms; or any radiation, surgery, or other therapy, including those used to control symptoms, within 1 month of first dose
Untreated or symptomatic brain metastases
Untreated brain metastases
Untreated or symptomatic brain metastases
Patients with untreated brain metastases
No symptomatic, untreated, or uncontrolled brain metastases present
Known untreated brain metastases
Active and/or untreated CNS disease or non-stable brain metastases
Untreated or progressive brain metastases; patients with treated brain metastases not requiring chronic corticosteroids for symptom control are eligible
Untreated or progressive brain metastases
Previously untreated brain metastases.
Patients with untreated or progressing brain metastases
Patients with either untreated brain metastases or brain metastases treated within the past three months are ineligible
Untreated and/or uncontrolled brain metastases.
Untreated brain metastases (or local treatment of brain metastases within the last 6 months)
Untreated brain metastases.
Patients with active or untreated brain metastases; treated brain metastases must have been stable for at least 2 months
Untreated or progressive brain metastases; patients with treated brain metastases not requiring chronic corticosteroids for symptom control are eligible
Untreated brain metastases
Patients with untreated symptomatic brain metastases will be excluded from this study; those with treated brain metastases or untreated but asymptomatic sub-centimeter brain metastases will be allowed as long as they are neurologically asymptomatic and off steroids
Subjects with previously untreated or uncontrolled brain metastases.
The participant has an untreated brain tumor
Known brain metastases, or untreated meningeal/dural disease
Untreated brain metastases. (Brain metastases that have been treated, which no longer require corticosteroid therapy and are without progression by MRI at least 6 weeks after definitive therapy are acceptable.)
Has known untreated or symptomatic brain metastases;
Untreated brain metastasis; patients with treated brain metastases who are off steroids are eligible
Untreated brain metastases
Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms
Brain metastases that are untreated or symptomatic or require any radiation, surgery,\n             or steroid therapy to control symptoms from brain metastases within 1 month of\n             randomization
Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms; or any radiation, surgery or other therapy to control symptoms from brain metastases within 2 months prior to first dose of MEDI4276.
Untreated brain metastases; brain metastases =< 1 cm and not associated with any focal neurologic deficits are allowed
Untreated brain metastases
Active, untreated brain metastases
Untreated brain metastases
Patients with known untreated brain metastases
Active or untreated brain metastases
Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms
Untreated brain metastases (or local treatment of brain metastases within the last three months)
Untreated brain metastases
Brain metastases that are symptomatic or untreated or that require current therapy.
Participant has untreated brain or meningeal metastases.
Symptomatic and/or untreated brain metastases
Untreated brain metastases
Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms
Patients with known untreated and uncontrolled brain metastases are excluded. However, brain-imaging studies are not required for eligibility if the patient has no neurological signs or symptoms.